# Enlivex Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Enlivex Ltd.).

## Overview

Enlivex Ltd. is an Israel-based clinical-stage biotechnology company focused on developing Allocetra™, an immunotherapy platform for inflammatory conditions associated with aging, including age-related osteoarthritis. The company is headquartered in Nes Ziona, Israel and is publicly listed on Nasdaq; it also manages a digital asset treasury tied to the Rain prediction markets protocol.

## Products & services

• Allocetra™ immunotherapy for inflammatory conditions
• Clinical-stage development for age-related osteoarthritis
• Research and development of aging-related therapeutics
• Treasury management tied to RAIN tokens
• Digital-asset exposure via prediction markets infrastructure

- **Clinical-stage immunotherapy** (60%) — Development of Allocetra™ and related therapeutic candidates for inflammatory and aging-related conditions.
- **Digital asset treasury** (40%) — Treasury holdings and related market exposure built around the RAIN token and prediction markets ecosystem.

- Allocetra™ immunotherapy for inflammatory conditions
- Clinical-stage development for age-related osteoarthritis
- Research and development of aging-related therapeutics
- Treasury management tied to RAIN tokens
- Digital-asset exposure via prediction markets infrastructure

## Customers

Enlivex's therapeutic work is aimed at patients with inflammatory conditions associated with aging, especially age-related osteoarthritis, through future clinical and commercial pathways. Its treasury strategy does not involve conventional product customers in the usual sense; rather, it is exposed to token holders, exchange participants, and the broader digital-asset market that determines the value of RAIN.

- **Patients with age-related inflammatory disease** (primary) — Future end users of Allocetra™ if the therapy advances and is commercialized for osteoarthritis or related indications.
- **Clinical investigators and trial sites** (primary) — Hospitals, physicians, and research centers that conduct the studies needed to advance Allocetra™.
- **Pharma partners and licensees** (secondary) — Potential collaborators that may buy rights, co-develop assets, or fund development programs.
- **Digital-asset market participants** (primary) — Users and traders whose demand, liquidity, and pricing determine the value of RAIN treasury holdings.
- **Tokenized-equity investors** (secondary) — Non-U.S. investors gaining exposure to Enlivex ordinary shares through ENLVon on Ondo Global Markets.

- Patients with inflammatory aging-related conditions
- Physicians and clinical sites running immunotherapy studies
- Potential future biopharma partners or licensees
- Digital-asset market participants affecting RAIN liquidity
- Non-U.S. investors accessing tokenized ENLV shares

## Geography

Enlivex is headquartered in Nes Ziona, Israel, and its operating footprint is centered on Israeli corporate and research activities. The company is listed in the United States on Nasdaq, while its treasury exposure reaches into global digital-asset markets through RAIN and tokenized equity distribution channels.

- **Israel** (60%) — Headquarters and core operations are based in Nes Ziona.
- **United States** (20%) — Nasdaq listing and U.S. capital market presence.
- **International** (20%) — Digital-asset treasury and tokenized share distribution are global.

- Headquartered in Nes Ziona, Israel
- Corporate and research base in Israel
- Nasdaq listing provides U.S. capital access
- RAIN treasury exposes the firm to global crypto markets
- ENLVon expands reach to non-U.S. investors

## Strategy

Enlivex is pursuing a dual strategy: advance Allocetra™ as a clinical-stage immunotherapy while maintaining a treasury positioned around the Rain prediction markets protocol. This creates optionality between long-duration biotech development and exposure to a digital-asset ecosystem that can support treasury value and market visibility.

- **Advance Allocetra™ clinical programs** (medium-term) — Clinical progress is the core value driver for the biotechnology business.
- **Scale and preserve treasury exposure** (short-term) — RAIN holdings are intended to support net asset value and strategic flexibility.
- **Expand investor access through tokenization** (short-term) — Tokenized distribution can broaden the shareholder base and improve liquidity access.

- Advance Allocetra™ through clinical development
- Target age-related osteoarthritis as a lead indication
- Build value around the Rain prediction markets treasury
- Use digital infrastructure to broaden investor access
- Maintain strategic optionality across biotech and digital assets

## Risks

Enlivex faces typical clinical-development risk because Allocetra™ must prove safety, efficacy, and commercial relevance before it can create operating value. The treasury strategy adds a separate layer of risk from highly volatile digital-asset prices, liquidity, exchange access, and evolving regulatory treatment of crypto assets.

- **Clinical development failure** [high] — Allocetra™ is still in clinical-stage development and may not demonstrate sufficient safety or efficacy.
- **Digital asset volatility** [high] — The company’s treasury value depends heavily on RAIN token price, liquidity, and trading volume.
- **Regulatory uncertainty in crypto** [medium] — Digital assets face changing legal, commercial, and tax frameworks across jurisdictions.
- **Financing and dilution risk** [medium] — Biotech development and treasury execution may require additional capital or convertible financing.

- Clinical trials may fail to show efficacy or safety
- Osteoarthritis development can be slow and capital intensive
- RAIN token value is highly volatile and liquidity-sensitive
- Crypto regulation and tax treatment remain uncertain
- Treasury value may move with digital asset market cycles

## Accounting

Investors should watch how Enlivex measures and discloses its RAIN token holdings, because fair-value changes can materially affect reported results and balance-sheet values. Clinical-stage biotech accounting also depends on judgment around R&D expense timing, capitalization policies, and the accounting for convertible financing, warrants, and other financial instruments.

- **Fair value of RAIN tokens** — Can create large unrealized gains or losses
- **Convertible promissory note** — Affects interest expense, liability balance, and dilution analysis
- **R&D expense recognition** — Determines timing of biotech spending recognition
- **Digital asset disclosures** — Important for NAV and liquidity analysis

- Fair value measurement of RAIN token holdings
- Mark-to-market changes can drive reported volatility
- R&D expense timing affects clinical-stage losses
- Convertible note accounting may include embedded features
- Digital asset valuation requires judgment and market inputs

---

*Last updated: 2026-09-28T12:03:33.403352+00:00*